Low-dose recombinant alfa-2a-interferon: a feasible maintenance therapy in acute myeloid leukaemia in the older patient.

E.N. McSweeney,Colin P. Worman,Cp Tsakona,Ap Jewel,A. V. Hoffbrand,Donald Milligan,A. K. Burnett,M. L. Lewis,Anthony H. Goldstone

Low-dose recombinant alfa-2a-interferon: a feasible maintenance therapy in acute myeloid leukaemia in the older patient.

1993

E.N. McSweeney
Colin P. Worman
Cp Tsakona
Ap Jewel
A. V. Hoffbrand
Donald Milligan
A. K. Burnett
M. L. Lewis
Anthony H. Goldstone

Eleven patients with acute myeloid leukaemia (AML) in first complete remission (CR) were treated with alfa-2a-interferon (for short ‘interferon’) maintenance therapy, at a dose of 3 MU twice to thrice

Keywords:

Medicine
Interferon alfa
Immunology
Alpha interferon
Side effect
Myeloid
Immunotherapy
Maintenance therapy
Interferon
Tolerability
Diabetes mellitus
Cytokine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations